Title: Increased toxicity and retention of perflourooctane sulfonate (PFOS) in humanized CYP2B6-Transgenic mice compared to Cyp2b-null mice is relieved by a high-fat diet (HFD).
Authors: Hamilton, Matthew C; Heintz, Melissa M; Pfohl, Marisa; Marques, Emily; Ford, Lucie; Slitt, Angela L; Baldwin, William S
Published In Food Chem Toxicol, (2021 Jun)
Abstract: PFOS is a persistent, fluorosurfactant used in multiple products. Murine Cyp2b's are induced by PFOS and high-fat diets (HFD) and therefore we hypothesized that human CYP2B6 may alleviate PFOS-induced steatosis. Cyp2b-null and hCYP2B6-Tg mice were treated with 0, 1, or 10 mg/kg/day PFOS by oral gavage for 21-days while provided a chow diet (ND) or HFD. Similar to murine Cyp2b10, CYP2B6 is inducible by PFOS. Furthermore, three ND-fed hCYP2B6-Tg females treated with 10 mg/kg/day PFOS died during the exposure period; neither Cyp2b-null nor HFD-fed mice died. hCYP2B6-Tg mice retained more PFOS in serum and liver than Cyp2b-null mice presumably causing the observed toxicity. In contrast, serum PFOS retention was reduced in the HFD-fed hCYP2B6-Tg mice; the opposite trend observed in HFD-fed Cyp2b-null mice. Hepatotoxicity biomarkers, ALT and ALP, were higher in PFOS-treated mice and repressed by a HFD. However, PFOS combined with a HFD exacerbated steatosis in all mice, especially in the hCYP2B6-Tg mice with significant disruption of key lipid metabolism genes such as Srebp1, Pparg, and Hmgcr. In conclusion, CYP2B6 is induced by PFOS but does not alleviate PFOS toxicity presumably due to increased retention. CYP2B6 protects from PFOS-mediated steatosis in ND-fed mice, but increases steatosis when co-treated with a HFD.
PubMed ID: 33838175
MeSH Terms: Alkanesulfonic Acids/toxicity*; Animals; Cytochrome P-450 CYP2B6/genetics; Cytochrome P-450 CYP2B6/metabolism*; Diet, High-Fat*; Female; Fluorocarbons/toxicity*; Gene Expression/drug effects; Humans; Liver/drug effects; Liver/metabolism; Liver/pathology; Male; Mice, Transgenic; Non-alcoholic Fatty Liver Disease/chemically induced; Non-alcoholic Fatty Liver Disease/metabolism*; Non-alcoholic Fatty Liver Disease/pathology; Non-alcoholic Fatty Liver Disease/prevention & control*; Triglycerides/metabolism